Who is sponsoring NCT02230956?

NCT02230956 is sponsored by Allergan.

What condition does NCT02230956 study?

NCT02230956 studies Osteoarthritis.

What drugs are being tested in NCT02230956?

Interventions: onabotulinumtoxinA, Normal Saline.

What is the status of NCT02230956?

NCT02230956 is currently COMPLETED.

Last reviewed 2017-05-05 · How we verify

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

NCT02230956 Phase 2 COMPLETED Results posted

This study will evaluate the efficacy and safety of a single intra-articular injection of 2 doses of BOTOX® (onabotulinumtoxinA) compared with placebo as treatment for knee osteoarthritis symptoms.

Details

Lead sponsor	Allergan
Phase	Phase 2
Status	COMPLETED
Enrolment	176
Start date	2014-10
Completion	2016-03

Conditions

Osteoarthritis

Interventions

onabotulinumtoxinA
Normal Saline

Primary outcomes

Change From Baseline in the 7-Day Average Daily Pain Score Using an 11-Point Scale — Baseline, Week 8
Participants recorded the pain in their knee during the previous 24 hours in a daily diary where: 0=no pain to 10= worst pain possible. The daily pain scores over 7-days were averaged. A negative change from Baseline indicates improvement.

Countries

United States, Czechia, Denmark